Skip to main content

Inforsense Partners With Vendors to Create Integrated Software and Workflows

NEW YORK, March 11 (GenomeWeb News) - Inforsense announced this week the establishment of its Open Workflow Partner Network, a vendor network designed to provide interoperability between proprietary data sources and analytic reporting tools.

 

According to InforSense, the partner network to date includes Daylight, Lion Bioscience, and Elsevier MDL.

 

"Customers require choice in the tools that are most appropriate for their work, rather thansourcing all from a single vendor," said Yike Guo, CEO of InforSense. "Inforsense is the independent workflow provider, and this initiative is more thanjust an agreement with other vendors to work together.

 

"We have already commenced software integration programs with partners and together will deliver working solutions for our mutual customers," Guo added.

 

Inforsense is the maker of the Open Discovery Workflow informatics platforms. According to the company, the goal of the partner initiative is to build a network of vendors that span the full range of scientific tools, database and data cartridge suppliers, and data mining and visualization providers. InforSense will bring together its partners, providing an integrative workflow creation, as well as workflow warehousing and searching.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.